Syringeability of morphine ARER, a novel, abuse-deterrent, extended-release morphine formulation

References

• Centers for Disease Control and Prevention. Press release: opioid painkiller prescribing varies widely among states [Internet]. 2014 [accessed 2019 Feb 25]. www.cdc.gov/media/releases/2014/p0701-opioid-painkiller.html.
   Google Scholar
• Food and Drug Administration. Abuse-deterrent opioids - evaluation and labeling guidance for industry [Internet]. 2015 [accessed 2019 Feb 25]. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf.
   Google Scholar
• Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med. 2009;10(Suppl 2):S124–33. doi:10.1111/j.1526-4637.2009.00672.x.
   PubMed Web of Science ®Google Scholar
• Budman SH, Grimes Serrano JM, Butler SF. Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduct J. 2009;6:8. doi:10.1186/1477-7517-6-8.
   PubMed Web of Science ®Google Scholar
• Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37(4):205–17. doi:10.3109/00952990.2011.569623.
   PubMed Web of Science ®Google Scholar
• Gasior M, Bond M, Malamut R. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Postgrad Med. 2016;128(1):85–96. doi:10.1080/00325481.2016.1120642.
   PubMed Web of Science ®Google Scholar
• Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8:29. doi:10.1186/1477-7517-8-30.
   PubMed Web of Science ®Google Scholar
• Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction. 2012;107(7):1318–27. doi:10.1111/j.1360-0443.2012.03803.x.
   PubMed Web of Science ®Google Scholar
• Lankenau SE, Kecojevic A, Silva K. Associations between prescription opioid injection and Hepatitis C virus among young injection drug users. Drugs (Abingdon Engl). 2015;22(1):35–42. doi:10.3109/09687637.2014.970515.
   PubMedGoogle Scholar
• Conrad C, Bradley HM, Broz D, Buddha S, Chapman EL, Galang RR, Hillman D, Hon J, Hoover KW, Patel MR, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone–Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443–44.
   PubMed Web of Science ®Google Scholar
• Surratt H, Kurtz SP, Cicero TJ. Alternate routes of administration and risk for HIV among prescription opioid abusers. J Addict Dis. 2011;30(4):334–41. doi:10.1080/10550887.2011.609805.
   PubMed Web of Science ®Google Scholar
• Del Giudice P. Cutaneous complications of intravenous drug abuse. Br J Dermatol. 2004;150(1):1–10.
   PubMed Web of Science ®Google Scholar
• Ghuran A, van Der Wieken LR, Nolan J. Cardiovascular complications of recreational drugs. Bmj. 2001;323(7311):464–66.
   PubMed Web of Science ®Google Scholar
• DiFalco R, Kinzler ER, Pantaleon C, Aigner S. Abuse-resistant, extended-release moprhine is resistant to physical manipulation techniques commonly used by opioid abusers. Postgrad Med. 2014;126:S38–9.
   PubMed Web of Science ®Google Scholar
• Webster LR, Pantaleon C, Shah MS, DiFalco R, Iverson M, Smith MD, Kinzler ER, Aigner S. A randomized, double-blind, double-dummy, placebo-controlled, intranasal drug liking study on a novel abuse-deterrent formulation of morphine-morphine ARER. Pain Med. 2017;18(7):1303–13. doi:10.1093/pm/pnw213.
   PubMed Web of Science ®Google Scholar
• Bianchi R, Kinzler ER, DiFalco R, Shah MS, Aigner S. Extraction testion of a novel extended-release, abuse-deterrent formulation of morphine, Morphine ARER, in common household solvents. J Pain. 2014;15(4):S77(Abstract 404). doi:10.1016/j.jpain.2014.01.315.
   Web of Science ®Google Scholar
• United States Food and Drug Administration. FDA requests removal of Opana ER for risks related to abuse [Internet]. 2017 [accessed 2019 Feb 25]. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm.
   Google Scholar
• Gottlieb S, Woodcock J. Marshaling FDA benefit-risk expertise to address the current opioid abuse epidemic. Jama. 2017;318(5):421–22. doi:10.1001/jama.2017.9205.
   PubMed Web of Science ®Google Scholar
• Rahman Z, Yang Y, Korang-Yeboah M, Siddiqui A, Xu X, Ashraf M, Khan MA. Assessing impact of formulation and process variables on in-vitro performance of directly compressed abuse deterrent formulations. Int J Pharm. 2016;502(1–2):138–50. doi:10.1016/j.ijpharm.2016.02.029.
   PubMed Web of Science ®Google Scholar
• Rahman Z, Zidan AS, Korang-Yeboah M, Yang Y, Siddiqui A, Shakleya D, Khan MA, Cruz C, Ashraf M. Effects of excipients and curing process on the abuse deterrent properties of directly compressed tablets. Int J Pharm. 2017;517(1–2):303–11. doi:10.1016/j.ijpharm.2016.12.015.
   PubMed Web of Science ®Google Scholar
• Vosburg SK, Haynes C, Besharat A, Green JL. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the researched abuse, diversion, and addiction-related surveillance (RADARS) system web monitoring program. Pharmacoepidemiol Drug Saf. 2017;26(9):1044–52. doi:10.1002/pds.4248.
   PubMed Web of Science ®Google Scholar
• Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Benedek IH, Comer SD. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012;126(1–2):206–15. doi:10.1016/j.drugalcdep.2012.05.013.
   PubMed Web of Science ®Google Scholar
• Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Shapiro DY, Comer SD. A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin(R) (non-TRF) in prescription opioid abusers. Addiction. 2013;108(6):1095–106. doi:10.1111/add.12114.
   PubMed Web of Science ®Google Scholar